Modulating Th2 cell levels via vMIP-I/CCR8 interaction
OwnerJoseph A. Hedrickinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to the agonist properties of vMIP-I for the chemokine receptor CCR8 as expressed on Th2 cells. Methods of modulating a physiological signal specific to Th2 cells comprising contacting these cells with vMIP-I, agonists and antagonists thereof are disclosed. Methods for treating disease using CCR8 antagonists are also provided. The modulation of the Th2 cell populations through the vMIP-I/CCR8 interaction provides a new means for diagnosing and treating specific disease states and immunologic conditions.
Claims20
A method of modulating a physiological signal specific to Th2 cells, comprising contacting said Th2 cells with vMIP-I or an agonist or antagonist thereof.
A method of treating an HHV-8 viral infection in a mammal comprising administering to said mammal an effective amount of a CCR8 antagonist or a vMIP-I antagonist.
A method of treating an autoimmune disease in a mammal comprising administering to said mammal an effective amount of a CCR8 antagonist or vMIP-I antagonist.
A method of treating a bacterial or parasitic infection in a mammal comprising administering to said mammal an effective amount of a CCR8 agonist.
Dependencies are inferred from the claim text.